Merck, T8885-25VL, Thrombin from human plasma

General description
Thrombin is the final coagulation protease in regard to hemostasis, promoting both procoagulant and anticoagulant effects.
Application
Thrombin is used for site specific cleavage of recombinant fusion proteins containing an accessible thrombin recognition site for removal of affinity tags. Thrombin has been used in a study that compared efficacy and safety of low-molecular-weight heparins (LMWHs) to other anticoagulants as venous thromboembolism prophylaxis in major orthopedic surgery.
Biochem/physiol Actions
Serine protease that selectively cleaves Arg-Gly bonds in fibrinogen to form fibrin and fibrinopeptides A and B.
Preparation Note
When reconstituted with 1 ml H₂O, one vial will contain 10 mg bovine serum albumin, 0.15 M NaCl and 0.05 M sodium citrate, pH 6.5
Analysis Note
The NIH assay procedure uses 0.2 ml diluted plasma (1:1 with saline) as a substrate and 0.1ml of thrombin sample (stabilized in a 1% buffered albumin solution) based on a modification of the method of Biggs. Only clotting times in the range of 15-25 seconds are used for determining thrombin concentrations.
Other Notes
Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard
View more information on thrombin at www.sigma-aldrich.com/enzymeexplorer.
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.